News
The FDA has issued more than 200 complete response letters, which detail reasons for non-approval of drug applications.
BeOne Medicines has secured approval from the EC for Tevimbra (tislelizumab) to be used along with gemcitabine and cisplatin to treat NPC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback